Lonza Group Ag Net Change in Long-Term Investments 2012-2023 | LZAGY
Lonza Group Ag annual/quarterly net change in long-term investments history and growth rate from 2012 to 2023. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
- Lonza Group Ag net change in long-term investments for the quarter ending December 31, 2023 was $M, a NAN% increase year-over-year.
- Lonza Group Ag net change in long-term investments for the twelve months ending December 31, 2023 was $0M, a NAN% increase year-over-year.
- Lonza Group Ag annual net change in long-term investments for 2022 was $-0.003B, a 58.95% decline from 2021.
- Lonza Group Ag annual net change in long-term investments for 2021 was $-0.008B, a 68.78% decline from 2020.
- Lonza Group Ag annual net change in long-term investments for 2020 was $-0.025B, a 74.1% increase from 2019.
| Lonza Group Ag Annual Net Change in Long-Term Investments (Millions of US $) |
|
|---|---|
| 2022 | $-3 |
| 2021 | $-8 |
| 2020 | $-25 |
| 2019 | $-14 |
| 2017 | $-9 |
| 2016 | $-11 |
| 2015 | $ |
| 2014 | $ |
| 2013 | $ |
| 2012 | $ |
| 2011 | $ |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $42.382B | $7.478B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.757B | 25.10 |
| Stryker (SYK) | United States | $136.750B | 30.82 |
| Boston Scientific (BSX) | United States | $131.731B | 37.87 |
| EssilorLuxottica (ESLOY) | France | $109.710B | 0.00 |
| Medtronic (MDT) | Ireland | $102.865B | 15.28 |
| Haleon (HLN) | United Kingdom | $42.732B | 27.76 |
| GE HealthCare Technologies (GEHC) | United States | $35.810B | 18.57 |
| ResMed (RMD) | United States | $33.540B | 27.56 |
| Terumo (TRUMY) | Japan | $28.681B | 40.51 |
| Koninklijke Philips (PHG) | Netherlands | $23.480B | 17.97 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.795B | 13.24 |
| Insulet (PODD) | United States | $18.017B | 71.75 |
| Baxter (BAX) | United States | $14.940B | 9.72 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.606B | 38.65 |
| Bio-Rad Laboratories (BIO) | United States | $9.131B | 31.03 |
| Demant (WILYY) | Denmark | $8.251B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.174B | 14.35 |
| Haemonetics (HAE) | United States | $3.938B | 19.22 |
| ICU Medical (ICUI) | United States | $3.868B | 36.83 |
| Prestige Consumer Healthcare (PBH) | United States | $3.840B | 19.10 |
| Perrigo (PRGO) | Ireland | $3.547B | 10.44 |
| Envista Holdings (NVST) | United States | $3.289B | 24.50 |
| QuidelOrtho (QDEL) | United States | $3.029B | 19.50 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.863B | 18.36 |
| Neogen (NEOG) | United States | $2.587B | 29.85 |
| LeMaitre Vascular (LMAT) | United States | $2.057B | 49.98 |
| Green Thumb Industries (GTBIF) | United States | $1.724B | 30.17 |
| AtriCure (ATRC) | United States | $1.482B | 0.00 |
| InMode (INMD) | Israel | $1.424B | 8.57 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.386B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.305B | 9.33 |
| BioLife Solutions (BLFS) | United States | $1.214B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.066B | 0.00 |
| Owens & Minor (OMI) | United States | $0.991B | 7.74 |
| CeriBell (CBLL) | United States | $0.926B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.840B | 14.81 |
| Evolus (EOLS) | United States | $0.704B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.680B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.594B | 26.20 |
| Omeros (OMER) | United States | $0.570B | 0.00 |
| Surmodics (SRDX) | United States | $0.567B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.502B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.463B | 0.00 |
| Quanterix (QTRX) | United States | $0.415B | 0.00 |
| Valneva SE (VALN) | France | $0.384B | 0.00 |
| ZimVie (ZIMV) | United States | $0.382B | 32.16 |
| Biote (BTMD) | United States | $0.328B | 7.18 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.11 |
| Canopy Growth (CGC) | Canada | $0.314B | 0.00 |
| Cerus (CERS) | United States | $0.292B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.289B | 0.00 |
| High Tide (HITI) | Canada | $0.269B | 110.67 |
| OraSure Technologies (OSUR) | United States | $0.264B | 17.70 |
| Zynex (ZYXI) | United States | $0.249B | 52.07 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.208B | 14.37 |
| MacroGenics (MGNX) | United States | $0.207B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.180B | 95.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.152B | 0.00 |
| Jin Medical (ZJYL) | China | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.148B | 18.59 |
| Quipt Home Medical (QIPT) | United States | $0.125B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.097B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.072B | 37.00 |
| Jushi Holdings (JUSHF) | United States | $0.065B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.060B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.049B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Safety Shot (SHOT) | United States | $0.045B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.027B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.84 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |